Corebridge Financial Inc. Sells 4,714 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Corebridge Financial Inc. lowered its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 4.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 109,090 shares of the biotechnology company's stock after selling 4,714 shares during the period. Corebridge Financial Inc. owned 0.11% of Sarepta Therapeutics worth $13,264,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in Sarepta Therapeutics by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company's stock valued at $1,104,701,000 after acquiring an additional 117,904 shares during the last quarter. Janus Henderson Group PLC lifted its stake in Sarepta Therapeutics by 14.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock valued at $544,408,000 after purchasing an additional 543,143 shares during the last quarter. Wellington Management Group LLP grew its holdings in Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock worth $340,527,000 after purchasing an additional 665,087 shares during the period. Geode Capital Management LLC increased its position in Sarepta Therapeutics by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock worth $211,910,000 after buying an additional 44,306 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its stake in Sarepta Therapeutics by 9.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company's stock valued at $94,148,000 after buying an additional 63,437 shares during the period. Institutional investors and hedge funds own 86.68% of the company's stock.

Remove Ads

Insider Transactions at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 7.70% of the company's stock.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock traded down $1.40 during midday trading on Friday, reaching $70.41. The company's stock had a trading volume of 984,471 shares, compared to its average volume of 1,256,653. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a market cap of $6.83 billion, a PE ratio of 56.33 and a beta of 0.79. Sarepta Therapeutics, Inc. has a 52 week low of $69.81 and a 52 week high of $173.25. The business has a 50-day moving average price of $102.66 and a 200-day moving average price of $115.99.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft reduced their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research note on Wednesday, March 19th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. HC Wainwright restated a "sell" rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, March 19th. Royal Bank of Canada decreased their price target on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an "outperform" rating on the stock in a research note on Thursday, February 27th. Finally, Scotiabank cut their price objective on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research report on Thursday, March 20th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $167.41.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.